Roche launches new HIV and hepatitis C assays

Roche has announced the launch of its new Cobas HIV-1 and Cobas hepatitis C virus assays in Europe and other markets that recognise CE Mark accreditation.

Designed for use on the Cobas 6800/8800 Systems, these next-generation viral load testing assays offer a high quality of performance and will help to improve the medical community's understanding of viral disease and ability to treat patients.

In the coming months, the company will also launch new assays for cytomegalovirus and hepatitis B, thus completing the primary portfolio of viral load monitoring assays for the Cobas 6800/8800 Systems.

This viral load portfolio is designed to provide laboratories with improved productivity and the ability to deliver results for rapid clinical decisions.

Roland Diggelmann, chief operating officer of Roche Diagnostics, said: "The cobas 6800/8800 Systems represent the next generation of molecular diagnostic instruments that offer unparalleled performance, unmatched flexibility and absolute automation."

Earlier this month, the company announced the acquisition of Ariosa Diagnostics, allowing Roche to enter the non-invasive prenatal test and cell-free DNA testing services markets for the first time.